Biogen Inc. will move beyond neurological, rare and autoimmune diseases and into ophthalmology with its planned acquisition of UK-based Nightstar Therapeutics PLC, thereby getting two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.
Biogen on March 4 said it was buying the gene therapy biotech for about $877m in cash, and that the...








